ECFS 2020 - Optimizing pharmaceutical care in cystic fibrosis

European Cystic Fibrosis Society   259  OPTIMIZING PHARMACEUTICAL CARE IN CYSTIC FIBROSIS PATIENTS’ PRIORITIES AND THE CF PHARMACEUTICAL PIPELINE CHAPTER 14 References [1] Easterbrook PJ, Berlin JA, Gopalan R, Matthews DR. Publication bias in clinical research. Lancet. 1991;337(8746):867-72. [2] Rowbotham NJ, Smith S, Leighton PA, Rayner OC, Gathercole K, Elliott ZC, et al. The top 10 research prior- ities in cystic fibrosis developed by a partnership between people with CF and healthcare providers. Thorax. 2018;73(4):388-90. [3] Hollin IL, Donaldson SH, Roman C, Aliaj E, Riva D, Boyle M, et al . Beyond the expected: Identifying broad research priorities of researchers and the cystic fibrosis community. J Cyst Fibros. 2019;18(3):375-7. [4] Buzzetti R, Galici V, Cirilli N, Majo F, Graziano L, Costa S, et al. Defining research priorities in cystic fibrosis. Can existing knowledge and training in biomedical research affect the choice? J Cyst Fibros. 2019;18(3):378- 81. [5] Noordhoek JJ, Gulmans VAM, Heijerman HGM, van der Ent CK. Aligning patients’ needs and research priorities towards a comprehensive CF research program.J Cyst Fibros. 2019;18(3):382-4. [6] Cowan K. The James Lind Alliance Guidebook Southampton, UK: James Lind Alliance; 2018. Available from: book/downloads/Version-8-JLA- Guidebook-for-download-from-web- site.pdf . [7] Rowbotham NJ, Smith SJ, Elliott ZC, Leighton PA, Rayner OC, Morley R, et al. Adapting the James Lind Alliance priority setting process to better support patient participation: an example from cystic fibrosis. Research involvement and engage- ment. 2019;5:24. [8] Rowbotham NJ, Smyth AR. Patient engagement to prioritise CF research: Inclusive or selective? J Cyst Fibros. 2019;18(3):307-8. [9] Liberati A. Need to realign patient-oriented and commercial and academic research. Lancet. 2011;378(9805):1777-8.